company background image
BCYC logo

Bicycle Therapeutics NasdaqGS:BCYC Rapport sur les actions

Dernier prix

US$19.95

Capitalisation boursière

US$1.4b

7D

-2.5%

1Y

43.3%

Mise à jour

25 Nov, 2024

Données

Finances de l'entreprise +

Bicycle Therapeutics plc

NasdaqGS:BCYC Rapport sur les actions

Capitalisation boursière : US$1.4b

BCYC Aperçu des actions

Bicycle Therapeutics plc, une société biopharmaceutique en phase clinique, développe une classe de médicaments pour des maladies qui sont mal desservies par les thérapies existantes aux États-Unis et au Royaume-Uni. Plus de détails

BCYC analyse fondamentale
Score flocon de neige
Évaluation0/6
Croissance future2/6
Performances passées0/6
Santé financière6/6
Dividendes0/6

Bicycle Therapeutics plc Concurrents

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Bicycle Therapeutics
Historique des cours de bourse
Prix actuel de l'actionUS$19.95
Plus haut sur 52 semainesUS$28.67
Plus bas sur 52 semainesUS$13.31
Bêta0.89
1Variation sur 1 mois-19.33%
Variation sur 3 mois-11.33%
Variation sur 1 an43.32%
3Variation sur 3 ans-63.07%
Variation sur 5 ans137.22%
Évolution depuis l'introduction en bourse66.25%

Nouvelles et mises à jour récentes

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Nov 07

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 03
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Recent updates

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Nov 07

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 03
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

May 24

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

May 04
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Apr 19
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Rendement pour les actionnaires

BCYCUS BiotechsUS Marché
7D-2.5%4.0%2.2%
1Y43.3%18.3%32.6%

Rendement vs Industrie: BCYC a dépassé le secteur US Biotechs qui a rapporté 18.3 % au cours de l'année écoulée.

Rendement vs marché: BCYC a dépassé le marché US qui a rapporté 32.6 % au cours de l'année écoulée.

Volatilité des prix

Is BCYC's price volatile compared to industry and market?
BCYC volatility
BCYC Average Weekly Movement9.9%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Cours de l'action stable: BCYC n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de BCYC ( 10% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
2009284Kevin Leewww.bicycletherapeutics.com

Bicycle Therapeutics plc, une société biopharmaceutique en phase clinique, développe une classe de médicaments pour les maladies qui sont mal desservies par les thérapies existantes aux États-Unis et au Royaume-Uni. Son portefeuille de produits comprend BT8009, un conjugué de toxine cycliste (BTC) qui est en phase I/II/III d'essai clinique pour le traitement des tumeurs exprimant fortement la nectine 4 ; BT5528, un BTC qui est en phase I/II d'essai clinique pour le traitement des tumeurs exprimant le récepteur 2 de l'éphrine ; BT7480, une molécule TICA de bicyclette en phase I/II ciblant la Nectine-4 et agonisant le CD137 ; et BT7455, une molécule TICA de bicyclette ciblant le récepteur 2 de l'Ephrine de type A et le CD137, qui est en phase d'essai préclinique. La société développe également le BT1718, un conjugué de toxine bicyclette (BTC), qui est en phase I/IIa d'essais cliniques ciblant les tumeurs qui expriment la métalloprotéase matricielle de type membrane 1 ; et le BT7401, un agoniste multivalent de CD137 bicyclette qui est en phase IIa pour traiter les tumeurs solides avancées.

Bicycle Therapeutics plc Résumé des fondamentaux

Comment les bénéfices et les revenus de Bicycle Therapeutics se comparent-ils à sa capitalisation boursière ?
BCYC statistiques fondamentales
Capitalisation boursièreUS$1.42b
Bénéfices(TTM)-US$166.28m
Recettes(TTM)US$36.90m

37.3x

Ratio P/S

-8.3x

Ratio P/E

Le site BCYC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
BCYC compte de résultat (TTM)
RecettesUS$36.90m
Coût des recettesUS$168.05m
Marge brute-US$131.15m
Autres dépensesUS$35.12m
Les revenus-US$166.28m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-2.41
Marge brute-355.45%
Marge bénéficiaire nette-450.64%
Ratio dettes/capitaux propres0%

Quelles ont été les performances à long terme de BCYC?

Voir les performances historiques et les comparaisons